Answers are grounded in this paper and cite their sources.
Introduction: Glioblastoma (GBM) is the most aggressive primary brain cancer in adults. The standard of care of newly diagnosed GBM, including radiotherapy with concurrent and adjuvant chemotherapy with temozolomide, was established more than 10 years ago. Despite this very intensive and multimodal therapeutic regimen, the prognosis of GBM patients remains grim. New treatments are urgently needed. Immunotherapy is changing perspectives in oncology and has raised of lot of hope for brain tumor patients.Areas covered: We will review molecular and cellular actors involved in immune response against GBM cells. Then, we will discuss the drugs modulating these immune molecular and cellular targets including passive and active immunotherapies.Expert commentary: Results obtained from studies using immunotherapy in GBM are encouraging and multiple promising phase III clinical trials are ongoing. Better outcomes with immunotherapies, alone or in combination, are expected in at least subpopulations of patients exhibiting peculiar histomolecular and/or immunologic patterns.
No takes yet. Share an insight, caveat, or question.
Them et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: